Man Group’s ImmunityBio IBRX Stock Holding History

Man Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,173	Closed	-$163K	–	2476
2025 Q4	$163K	Sell	82,173 -19,327	-19%	-$43.8K	﹤0.01%	2154
2025 Q3	$250K	Buy	+101,500	New	+$261K	﹤0.01%	2065
2023 Q3	–	Sell	-10,242	Closed	-$28.5K	–	2019
2023 Q2	$28.5K	Buy	+10,242	New	+$29K	﹤0.01%	1922
2022 Q4	–	Sell	-22,600	Closed	-$112K	–	2082
2022 Q3	$112K	Buy	+22,600	New	+$103K	﹤0.01%	1842
2022 Q2	–	Sell	-23,469	Closed	-$94.3K	–	1961
2022 Q1	$132K	Buy	+23,469	New	+$144K	﹤0.01%	2022

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Man Group's IBRX Position: Q1 2026 in Review

Man Group sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 82,173 shares — an estimated $163K sold.

Man Group first reported a position in IBRX in Q1 2022 and held it in 5 quarters. The position peaked at $250K in Q3 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Man Group reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Man Group sold 82,173 ImmunityBio shares in Q1 2026, an estimated $163K.
Man Group first reported a position in ImmunityBio in Q1 2022 and held it in 5 quarters.
Man Group's ImmunityBio position peaked at $250K in Q3 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.